NDAINTRAMUSCULARSOLUTION
Approved
Apr 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
FASLODEX (fulvestrant) by AstraZeneca is estrogen receptor antagonists [moa]. Approved for breast cancer, metastatic breast cancer, advanced breast cancer and 1 more indications. First approved in 2002.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FASLODEX (fulvestrant) is an estrogen receptor antagonist administered intramuscularly for hormone receptor-positive breast cancer. It works by binding to and degrading estrogen receptors, blocking estrogen-driven tumor growth. Approved in 2002, it treats metastatic, locally advanced, and advanced breast cancer across multiple tumor types.
$0.293MPart D
LOE ApproachingDeclining
FASLODEX faces significant competitive pressure (score: 30) and approaching loss of exclusivity, signaling potential team restructuring and reduced commercial investment.
Mechanism of Action
Estrogen Receptor Antagonists
Pharmacologic Class:
Estrogen Receptor Antagonist
Indications (4)
Worked on FASLODEX at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.